Thymosin Beta 4 5mg/vial 1 Vial by Master Pharma

Usage

1. Inspect the lyophilised vial — powder should be white and intact; discard if discoloured or clumped.
2. Reconstitute with 1–2 mL bacteriostatic water, injecting slowly along the vial wall with a fresh insulin syringe to preserve peptide structure.
3. Swirl gently — never shake — until fully dissolved; solution should be clear and colourless.
4. Calculate your dose: for 2.5 mg per injection with 1 mL total volume, draw 0.5 mL per injection.
5. Administer subcutaneously in the abdomen or thigh using a 28–31 gauge insulin syringe; rotate injection sites across each PCT week.
6. Refrigerate reconstituted vial at 2–8 °C immediately after drawing; use within 28 days and label the vial with the reconstitution date.

Warnings

Frequently asked questions

Does TB-500 suppress natural testosterone production during PCT?

TB-500 does not suppress the HPG axis. It operates through actin-binding and integrin-mediated repair pathways that are entirely separate from androgen receptor signalling. This makes it compatible with SERM-based PCT protocols — tamoxifen or clomiphene can run concurrently without pharmacological interference from the peptide.

Which peptides are appropriate to use during a bridge between steroid cycles?

Peptides with no hormonal activity are best suited for a bridge phase. TB-500 is a primary candidate because its mechanism — G-actin sequestration and fibroblast recruitment — does not engage the endocrine system. BPC-157 is a common companion for localised healing, while TB-500 handles broader connective tissue maintenance throughout the off-cycle window.

How does TB-500 protect joints after a steroid cycle ends?

After cycle cessation, reduced androgenic tone lowers collagen synthesis rates, increasing joint vulnerability. TB-500 counteracts this by upregulating β4-integrin expression and promoting fibroblast-driven extracellular matrix repair. In practice, this translates to reduced tendon stiffness and faster recovery from sub-acute joint inflammation that commonly emerges in the first weeks of PCT.

Why choose the 5mg/vial format for PCT rather than a higher-concentration vial?

The 5 mg/vial is the lowest concentration available in this product group, which makes it ideal for PCT: the entire vial contents cover a standard two-week loading protocol at 2.5 mg twice weekly with zero waste. Higher-concentration vials require either partial reconstitution storage or accepting unused compound, neither of which is optimal for a short-duration PCT window.

How should the Master Pharma TB-500 5mg vial be reconstituted and stored once opened?

Reconstitute with 1–2 mL bacteriostatic water using an insulin syringe, injecting slowly down the vial wall to avoid foaming. Once reconstituted, store at 2–8 °C (standard refrigeration) and use within 28 days. Draw doses with an insulin syringe (28–31 gauge) for subcutaneous administration. Do not freeze the reconstituted solution. (2) angle_used

Manufacturer

Master Pharma's long-standing position in the peptide market is reflected not only in brand recognition but in the consistency of its release standards across successive production years — a consistency that new entrants rarely achieve at scale. For the TB-500 5mg/vial SKU, that consistency is anchored to a two-instrument, two-method release requirement: identity and potency must be confirmed by HPLC against a traceable reference standard, and endotoxin burden must be quantified by LAL (Limulus Amebocyte Lysate) assay against parenteral safety thresholds. Both results are recorded on the lot-specific Certificate of Analysis, which ships with the batch — not as a generic product-level document, but as a lot-identified record directly tied to the vials the customer receives. This traceability infrastructure, maintained across years of commercial operation, is what distinguishes an established manufacturer's output from opportunistic contract filling.